** Drugmaker Biohaven's BHVN.N shares jump 8.4% to $21.51 premarket
** BHVN announces up to $600 million investment from investment firm Oberland Capital in exchange for capped milestone and royalty payments on future global net sales of its experimental drug, troriluzole
** Troriluzole is currently in late-stage development for obsessive-compulsive disorder (OCD), pending approval from the U.S. Food and Drug Administration
** Oberland may purchase up to $600 million of BHVN's bonds, of which $250 million will be funded before April end
** Covington & Burling served as legal adviser to Biohaven while Cooley advised Oberland
** All 16 brokerages covering the stock rate "buy" or higher; median PT $60 - data compiled by LSEG
** As of last close, BHVN stock down 47% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。